Treating kidney cancer – a review
DOI:
https://doi.org/10.15584/ejcem.2020.1.8Keywords:
kidney cancer, malignant tumors, MRIAbstract
Introduction. Kidney cancer in the structure of registered cases was in 6th place in men and 8th in women.
Aim. Understanding the molecular biology of renal cell carcinoma has made it possible to produce new diagnostic methods.
Material and methods. This review was performed according to a systematic literature search.
Analysis of the literature. Minimally invasive techniques seem to have a bright future in kidney cancer. However, they still require many clinical trials before they enter the general clinical use.
Conclusion. Photodynamic therapy, thanks to research conducted in kidney cancer, will find application in cancer of other organs.
Downloads
References
Epidemiologia. Krajowy Rejestr Nowotworów Web site. http://onkologia.org.pl/k/epidemiologia/
Nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów Web site. http://onkologia.org.pl/wp-content/uploads/Nowotwory_2015.pdf
Nowotwory złośliwe nerki. Krajowy Rejestr Nowotworów Web site. http://onkologia.org.pl/nowotwory-zlosliwe-nerki-c67/#e
Raport NIZP-PZH: onkologiczna mapa Polski. Serwis Zdrowie Web site. https://zdrowie.pap.pl/raport/onkologiczna-mapa-polski
Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604–614.
Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–1315.
Ficarra V, Schips L, Guille F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104:968–974.
Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173:1889–1892.
Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166:54–58.
Klatte T, Patard JJ, Goel RH, et al. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007;178:35–40; discussion 40.
Lam JS, Klatte T, Patard JJ, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007;52:155–162.
Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer. 2002;94:2590–2595.
Dall’Oglio MF, Antunes AA, Sarkis AS, et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int. 2007;100:552–555.
Dall’Oglio MF, Ribeiro-Filho LA, Antunes AA, et al. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol. 2007;178:425–428; discussion 428.
Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103:2517–2525.
Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511–520.
Capitanio U, Montorsi F. Renal cancer. Published Online August 26, 2015.
Woldrich JM, Palazzi K, Stroup SP, et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008. BJU Int. 2013; 111:1261–1268.
Ljungberg B, Bensalah K, Canfi eld S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67:913–924.
Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60 (1):40–49.
Katsanos K, Mailli L, Krokidis M, McGrath A, Sabharwal T, Adam A. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol. 2014;37:427–437.
Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J Urol. 2008; 179:1227–1233.
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015;13:151–159.
Funahashi Y, Hattori R, Yamamoto T, et al. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol. 2009;55:209–215.
Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171:1066–1070.
Hollingsworth JM, Miller DC, Dunn RL, et al. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology. 2006;67:1175–1180.
Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep. 2006;7:31–38.
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017;15(6):804–834.
Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7:735–740.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468–471.
Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012;188:51–57.
Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010;76:631–637.
Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55:28–34.
Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60:1212–1220.
Kuczyk M, Munch T, Machtens S, et al. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int. 2002;89:517–522.
Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol. 2005;48:252–257.
Ljungberg B. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep. 2013;14(1):19-25.
Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regi-mens for metastatic renal cancer. J Urol. 2003;170:141–1145.
Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14–27.
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francaisd’Immunotherapie. N Engl J Med. 1998;338:1272–1278.
Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding theimportance of smart drugs in renal cell carcinoma. Eur Urol. 2006;49:633–643.
Escudier B, Eisen T, Stadler WM, et al. TARGET StudyGroup. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl JMed. 2007;356:115–124.
Bozzini G, Colin P, Betrouni N, et al. Photodynamic therapy in urology: What can we do now and where are we heading; Elsevier Review; Available online 22 February 2012
Pomer S, Grashev G, Sinn H, Kalble T, Staehler G. Laser induced fluorescence diagnosis and photodynamic therapy of human renal cell carcinoma. Urologia Internationalis. 1995;55(4):197-201.
Wessels JT, Busse AC, Rave-Frank M. Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro. Photochemistry and Photobiology. 2008;84(1):228-235.
Popken G, Wetterauer U, Schultze-Seemann W. Kidney preserving tumour resection in renal cell carcinoma with photodynamic detection by 5-aminolaevulinic acid: preclinical and preliminary clinical results. BJU International. 1999;83(6):578-582.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
